Why the study?
Risk assessment models for VTE and bleeding in hospitalized medical patients inform thromboprophylaxis use, but an optimal approach for selecting risk factors was needed.
What are the key risk factors to include in risk assessment models for VTE and bleeding in hospitalized medical patients?
What are the key risk factors to include in risk assessment models for VTE and bleeding in hospitalized medical patients?
A novel systematic and expert-consensus approach identified key risk factors for VTE and bleeding in medical inpatients, highlighting acute infection as a novel VTE risk factor.
Answers are grounded in this paper and cite their sources.
Novel RAM selection method may refine VTE prophylaxis; leaves open whether updated models improve outcomes in medical inpatients.
Risk assessment models (RAMs) for venous thromboembolism (VTE) and bleeding in hospitalized medical patients inform appropriate use of thromboprophylaxis. Our aim was to use a novel approach for selecting risk factors for VTE and bleeding to be included in RAMs. First, we used the results of a systematic review of all candidate factors. Second, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of the evidence for the identified factors. Third, we using a structured approach to select factors to develop the RAMs, by building on clinical and methodological expertise. The expert panel made judgments on whether to include, potentially include, or exclude risk factors, according to domains of the GRADE approach and the Delphi method. The VTE RAM included age >60 years, previous VTE, acute infections, immobility, acute paresis, active malignancy, critical illness, and known thrombophilia. The bleeding RAM included age ≥65 years, renal failure, thrombocytopenia, active gastroduodenal ulcers, hepatic disease, recent bleeding, and critical illness. We identified acute infection as a factor that was not considered in widely used RAMs. Also, we identified factors that require further research to confirm or refute their importance in a VTE RAM (eg, D-dimer). We excluded autoimmune disease which is included in the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) bleeding RAM. Our results also suggest that sex, malignancy, and use of central venous catheters (factors in the IMPROVE bleeding RAM) require further research. In conclusion, our study presents a novel approach to systematically identifying and assessing risk factors to be included or further explored during RAM development.
No takes yet. Share an insight, caveat, or question.
Darzi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: